Evinacumab’s story begins not in a pharmaceutical laboratory but in human DNA. Angiopoietin-like protein 3, or ANGPTL3, is a protein secreted by the liver that acts as a molecular brake on two key fat-processing enzymes: lipoprotein lipase and endothelial lipase. People born with rare loss-of-function mutations in the ANGPTL3 gene enjoy lifelong low levels of triglycerides and LDL cholesterol and, crucially, a substantially reduced risk of atherosclerotic cardiovascular disease. Large population studies and Mendelian randomization analyses confirmed that these genetic effects are causal, transforming ANGPTL3 from a curious biological observation into one of the most validated drug targets in modern cardiovascular medicine.

Evinacumab is a fully human IgG4 monoclonal antibody that binds and neutralizes ANGPTL3. By lifting the inhibitory brake that ANGPTL3 places on lipoprotein lipase, the drug accelerates the hydrolysis and clearance of triglyceride-rich lipoproteins and their remnants. Enhanced endothelial lipase activity, meanwhile, promotes lipoprotein remodeling and modulates HDL metabolism. What makes the drug especially valuable, however, is a second, independent mechanism: ANGPTL3 inhibition lowers LDL cholesterol through pathways that do not require functional LDL receptors. It speeds the processing of very-low-density and intermediate-density lipoproteins and clears their remnants before they can mature into LDL particles, an endothelial lipase-dependent route that bypasses the receptor defect at the heart of familial hypercholesterolemia.

That receptor independence is precisely why the drug matters for homozygous familial hypercholesterolemia, or HoFH, the most severe inherited form of high cholesterol. Patients with HoFH carry mutations in both copies of genes governing the LDL receptor pathway, leaving them with sky-high cholesterol from birth, accelerated atherosclerosis, and little response to statins, ezetimibe, or even PCSK9 inhibitors. The new review, conducted under PRISMA guidelines and registered in PROSPERO, gathered evidence from randomized controlled trials, open-label extensions, pediatric studies, and real-world cohorts to quantify just how much evinacumab helps this population.

The quantitative core of the analysis focused on 357 patients with hypercholesterolemia receiving the approved regimen of 15 milligrams per kilogram intravenously every four weeks. Across seven pooled studies, evinacumab reduced LDL cholesterol by an average of 48.56 percent, non-HDL cholesterol by 50.19 percent, apolipoprotein B by 40.51 percent, and triglycerides by 53.13 percent. Study-level LDL reductions ranged from 42 to 82 percent, but most cohorts clustered near the 50 percent mark despite patients already being on maximally tolerated lipid-lowering therapy. Sensitivity analyses that dropped one study at a time confirmed the robustness of the results, and long-term extension data together with real-world experience showed the effects are sustained over time.

The real-world evidence carries particular weight for clinicians. In observational cohorts, evinacumab enabled some patients to reduce or even discontinue lipoprotein apheresis, the grueling blood-filtering procedure that has long been the last resort for HoFH. Similar efficacy was observed in pediatric populations, and isolated reports describe regression of atherosclerotic plaque in severely affected young patients treated with intensive regimens that included the antibody. Regulators have taken note: the United States Food and Drug Administration has approved evinacumab for HoFH patients aged one year and older, the European Medicines Agency for patients from six months of age, and the latest European and American cholesterol guidelines have woven the drug into their treatment algorithms for patients who fail LDL targets on receptor-dependent therapies.

The picture in hypertriglyceridemia is more complicated, and more nuanced. Because the underlying trials did not report variability measures, the authors could only assess this field qualitatively. Early phase 1 work showed dose-dependent triglyceride reductions reaching 70 to 80 percent at the highest doses, and in patients with moderate hypertriglyceridemia triglycerides fell 81.8 percent versus 20.6 percent on placebo. But the story diverged by syndrome. In multifactorial chylomicronemia syndrome, where patients retain some residual lipoprotein lipase function, triglyceride reductions frequently exceeded 60 to 80 percent, and a phase 2b trial in pancreatitis-prone patients showed median triglyceride drops of 55.3 percent at four weeks and up to 95.7 percent by week 16. In familial chylomicronemia syndrome, where lipoprotein lipase is essentially absent, responses were far more limited and largely indistinguishable from placebo, suggesting that residual enzyme activity is a biological prerequisite for the drug’s triglyceride-lowering power.

Another clinically important wrinkle emerged: in some hypertriglyceridemic cohorts, LDL cholesterol transiently rose, in certain cases by more than 50 percent. The authors explain this counterintuitive effect through lipoprotein kinetics. Profoundly accelerated lipolysis of triglyceride-rich particles can transiently generate more remnant particles and LDL precursors, occasionally nudging measured LDL upward even as triglycerides plummet. In this setting, the authors argue, such shifts may be of secondary importance, because the primary therapeutic objective is preventing acute pancreatitis, a life-threatening complication of extreme triglyceride elevations. Still, the observation underscores that evinacumab’s effects are phenotype-dependent, and that monitoring strategies must adapt to the patient in front of the clinician.

The review is candid about its limitations. Clinical and methodological heterogeneity across the 17 studies precluded a global comparative meta-analysis, forcing the authors to restrict quantitative pooling to hypercholesterolemic patients on the approved dose. Potential overlap of participants across trials, extension studies, and real-world reports from the same development programs cannot be fully excluded, which may have artificially sharpened some pooled estimates, and the small number of studies made formal publication bias testing unreliable. Risk-of-bias assessment rated most randomized trials at low risk or with some concerns, while several non-randomized studies carried moderate to serious risk. Even so, the overall verdict is strikingly consistent: evinacumab delivers substantial, sustained lipid lowering, most convincingly in HoFH, where it achieves the near-impossible, roughly halving LDL cholesterol in patients whose receptors cannot do the job. Emerging evidence also supports a role in severe hypertriglyceridemia, especially multifactorial chylomicronemia, though the authors caution that further studies are needed to translate triglyceride reductions into proven reductions in pancreatitis and cardiovascular events. For a drug built on the biology of lucky mutants, evinacumab is rapidly becoming anything but a niche option.

Subject of Research: Efficacy of the ANGPTL3 inhibitor evinacumab across different lipid phenotypes

Article Title: Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis

Article References: Masson, W., Lobo, M., Mansur, M., Solis, C., & Nogueira, J. P. (2026). Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis. Advances in Therapy. https://doi.org/10.1007/s12325-026-03783-1

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03783-1

Keywords: evinacumab, ANGPTL3, LDL cholesterol, homozygous familial hypercholesterolemia, hypertriglyceridemia, chylomicronemia syndrome, monoclonal antibody, systematic review, meta-analysis, triglycerides, cardiovascular disease, lipid metabolism